An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of endocrinology"
DOI: 10.1530/eje-21-0509
Abstract: NTRK rearrangements represent a very rare genomic abnormality among all cancers, but can be detected in thyroid cancer with a non-negligible frequency of 2%. Dramatic clinical responses to therapies targeting NTRK chimeric proteins are now… read more here.
Keywords: response larotrectinib; thyroid carcinoma; carcinoma harboring; sqstm1 ntrk1 ... See more keywords